In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When Can You Ban Parallel Trade?

This article was originally published in Scrip

Executive Summary

Taking steps to prevent medicines being parallel exported from on EU country to another is always fraught with uncertainty, despite a succession of rulings on the matter by the Court of Justice of the EU. And a recent statement by Health Commissioner Vytenis Andriukaitis, appearing to conflict with action being taken by the commission's internal market directorate, has done little to clarify the situation.

You may also be interested in...



Belgium Imposes Selective Export Ban As COVID-19 Threatens Stocks

A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations? 

Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.

AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies

The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.

Topics

UsernamePublicRestriction

Register

SC029749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel